⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438014 | 1.00 | — | — | |
| SCHEMBL16193623 | 0.88 | — | — | |
| SCHEMBL25027507 | 0.80 | CA1 (0.36) | — | |
| SCHEMBL1764615 | 0.77 | HTR1A (0.40) | — | |
| SCHEMBL30148542 | 0.77 | — | — | |
| SCHEMBL9901104 | 0.77 | HTR1A (0.34) | — | |
| SCHEMBL9901210 | 0.77 | — | — | |
| SCHEMBL15306190 | 0.75 | — | — | |
| SCHEMBL9901496 | 0.75 | HTR1A (0.31) | — | |
| SCHEMBL29437993 | 0.75 | HTR1A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-11541052-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-01-03 | — | — | US | disclosed |
| EP-3390394-B1 | HYDANTOIN MODULATORS OF KV3 CHANNELS | AUTIFONY THERAPEUTICS LTD (GB) | 2022-05-25 | — | — | EP | disclosed |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-20210023084-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2021-01-28 | — | — | US | disclosed |
| US-20200377485-A1 | HYDANTOIN MODULATORS OF KV3 CHANNELS | AUTIFONY THERAPEUTICS LTD (GB) | 2020-12-03 | — | — | US | disclosed |
| US-20200360379-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2020-11-19 | — | — | US | disclosed |
| US-10835534-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-11-17 | — | — | US | disclosed |
| US-20200179385-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2020-06-11 | — | — | US | disclosed |
| US-9133175-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-9133175-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140323508-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2014-10-30 | — | — | US | disclosed |
| US-20140323508-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2014-10-30 | — | — | US | disclosed |
| EP-2788339-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2014-10-15 | — | — | EP | disclosed |
| EP-2649066-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| WO-2013083994-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-06-13 | — | — | WO | disclosed |
| WO-2012076877-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |